Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
All the vital news, analysis, and commentary curated by our industry experts.
Myasthenia Gravis Market Overview
The Myasthenia Gravis (MG) market size for the seven major markets (7MM) was $3 billion in 2022. The market will register a CAGR of more than 8% during 2022-2032. MG is the most common neuromuscular disorder, although it is still classified as a rare disease. It is an autoimmune and neuromuscular disease that is characterized by muscle weakness and fatigue. In most patients, the disease is initially localized and limited to the eye muscles. This weakness can give patients difficulty controlling eye and eyelid movement, facial expressions, chewing, and talking. In some cases, the disease progressively begins to affect respiratory muscles.
Myasthenia Gravis Market Outlook, 2022-2032 ($ Billion)
Buy the Full Report to Know More About the Myasthenia Gravis Market Forecast
The Myasthenia Gravis (MG) market research report offers an overview of Myasthenia Gravis, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the Myasthenia Gravis therapeutics market. The report provides information on market drivers, drug classes, and sponsors of Myasthenia Gravis.
|Market Size (2022)
|Key Countries (7MM)
|· The US
· The UK
|Key Drug Classes
· Acetylcholinesterase Inhibitors
· IgG Receptor Inhibitors
· Complement Inhibitors
· Other Classes
|· Horizon Therapeutics Plc
· Regeneron Pharmaceuticals
· Chugai Pharmaceutical Co Ltd/ Hoffmann-La Roche
· Immunovant Inc
· Alexion Pharmaceuticals Inc/AstraZeneca
|Enquire & Decide
|Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.
Myasthenia Gravis Market Drivers
- New DMTs entering the market will drive sales across all 7MM, especially in Europe where only Soliris was approved for use before 2022, with Vyvgart being the first IgG inhibitor coming to the market.
- Many of the DMTs and pipeline agents received an orphan drug designation, providing them with at least seven years of market exclusivity. This will therefore delay the potential entry of generics into the market for many of the products.
Myasthenia Gravis Market Segmentation by Countries
In 2022, the US represented the largest market for Myasthenia Gravis with over 70% of the 7MM sales in 2022
The key countries in the Myasthenia Gravis market are the US, the UK, Germany, France, Italy, Spain, and Japan. The major driver for the growth of the MG market across the 7MM during the forecast period is the entry of Vyvgart and Ultomiris into the market between the years 2021 and 2022. The entry of Vyvgart Hytrulo, Rystiggo, and Zilucoplan will further drive market growth.
Myasthenia Gravis Market Analysis by Countries, 2022 (%)
Buy the Full Report for Country Insights into the Myasthenia Gravis Market
Myasthenia Gravis Market Segmentation by Drug Classes
In 2022, complement inhibitors contributed the most sales to the Myasthenia Gravis market.
The key drug classes in the Myasthenia Gravis market are immunosuppressant, steroid, acetylcholinesterase inhibitors, IgG receptor inhibitors, complement inhibitors, and other classes. The current management of MG relies heavily on genericized off-label treatment, especially in patients with ocular MG. The introduction of newly approved DMTs and the entry of new pipeline drugs will heavily increase shares for IgG receptor inhibitors and complement inhibitor groups.
Myasthenia Gravis Market Analysis by Drug Classes, 2022 (%)
Buy the Full Report for Drug Class Insights into the Myasthenia Gravis Market
Myasthenia Gravis Market Segmentation by Sponsors
Some of the key sponsors associated with the Myasthenia Gravis market are:
- Horizon Therapeutics Plc
- Regeneron Pharmaceuticals
- Chugai Pharmaceutical Co Ltd/ Hoffmann-La Roche
- Immunovant Inc
- Alexion Pharmaceuticals Inc/AstraZeneca
Myasthenia Gravis Market Analysis by Sponsors, 2023
Buy the Full Report for Sponsor Insights into the Myasthenia Gravis Market
Segments Covered in this Report
Myasthenia Gravis Country Outlook (Value, $ Billion, 2022-2032)
- The US
- The UK
Myasthenia Gravis Drug Class Outlook (Value, $ Billion, 2022-2032)
- Acetylcholinesterase Inhibitors
- IgG Receptor Inhibitors
- Complement Inhibitors
- Other Classes
The report provides:
- Overview of Myasthenia gravis disease, classification of Myasthenia gravis according to the Myasthenia Gravis Foundation of America guideline, etiology, pathophysiology, and epidemiology of Myasthenia gravis.
- Current treatment options including product profiles for Myasthenia gravis marketed in the 7MM.
- Analysis of unmet needs and R&A strategies within the Myasthenia gravis market.
- Pipeline analysis including product profiles for leading candidates in the 7MM.
- Myasthenia gravis market outlook including revenue breakdown by market between the years 2022 and 2032.
Report deliverables include a PowerPoint report and an Excel-based forecast model
Forecast includes the 7 major markets (7MM)
Forecast covers the period 2022-2032
Reasons to Buy
Understand the trends shaping and driving the Myasthenia gravis market
Identify the innovative technologies and key players leading the Myasthenia gravis field
Recognize gaps and areas of unmet need within the Myasthenia gravis market
Determine the current and future outlook for Myasthenia gravis according to key opinion leaders (KOLs)
Track Myasthenia gravis sales from 2022-2032
Horizon Therapeutics Plc
Chugai Pharmaceutical Co Ltd
Alnylam Pharmaceuticals Inc
Table of Contents
1.2. Related Reports
2. Executive Summary
3. Disease Overview
3.1. Overview of Myasthenia Gravis
3.2. Myasthenia Gravis SWOT Analysis
3.3. Antibody Classification of Myasthenia Gravis
3.4. Classification of Myasthenia Gravis
3.5. MGFA Classification of Myasthenia Gravis
4.1. Diagnosed Prevalent Cases of MG
4.2. Age-Specific Trends in Diagnosed Prevalent Cases of MG
4.3. Sex-Specific Diagnosed Prevalent Cases of MG
4.4. Sources and Methodology for MG Prevalence
4.5. Sources and Methodology for MG
5. Current Treatment Options
5.1. Treatment Paradigm
5.2. Current Treatment Options
5.3. Current Treatment Options – KOL Perspective
5.4. Product Profile: Immunosuppressants (Tacrolimus, Cyclosporine, Azathioprine)
5.5. Product Profile: Corticosteroids (Prednisone, Hydrocortisone, Methylprednisone)
5.6. Product Profile: Acetylcholinesterase Inhibitors (Pyridostigmine, Neostigmine, Ambenonium)
5.7. Product Profile: IgG Inhibitors (Vyvgart, Vyvgart Hytrulo, Rystiggo)
5.8. Product Profile: Complement Inhibitors (Soliris, Ultomiris, Zilbrysq)
5.9. Product Profile: Other Classes (Rituxan)
6. Unmet Needs and Opportunities
6.1. Unmet Needs in Myasthenia Gravis
6.2. Cost of Disease Modifying Therapies
6.3. Prognostic Biomarkers
6.4. Public and Physician Awareness
6.5. Frequency of Administration
6.6. Standardization of Classification and Treatment Guidelines
7. R&D Strategies
7.1. Trends in Clinical Trial Design in Myasthenia Gravis
7.2. R&D strategies in Myasthenia Gravis
7.3. Trends in Deal-Making in Myasthenia Gravis
8. Pipeline Assessment
8.1. Myasthenia Gravis Pipeline Overview
8.2. Late-Stage Pipeline Agents for Myasthenia Gravis
8.3. Product Profile: Horizon Therapeutic’s Uplizna (inebilizumab)
8.4. Product Profile: Regeneron’s Pozelimab in Combination with Alnylam’s Cemdisiran
8.5. Product Profile: Roche’s Enspryng (satralizumab)
8.6. Product Profile: Immunovant’s batoclimab
8.7. Product Profile: Alexion’s/AstraZeneca’s gefurulimab
8.8. Product Profile: Janssen’s nipocalimab
9. Market Outlook
9.1. Myasthenia Gravis Market Forecast
9.2. Market Drivers and Barriers
10.1. Primary Research – KOL Information
10.2. About the Authors
11. Contact Us
Frequently asked questions
What was the Myasthenia Gravis market size in 2022?
The Myasthenia Gravis market size was $3 billion in 2022.
What is the Myasthenia Gravis market growth rate during 2022-2032?
The Myasthenia Gravis market will register a CAGR of more than 8% during 2022-2032.
Which was the leading country in the Myasthenia Gravis market in 2022?
In 2022, the US dominated the Myasthenia Gravis market across the 7MM.
Which was the leading drug class in the Myasthenia Gravis market?
In 2022, complement inhibitors accounted for the highest sales in the Myasthenia Gravis market.
Which are the leading sponsors in the Myasthenia Gravis market?
Some of the key sponsors associated with the Myasthenia Gravis market are Horizon Therapeutics Plc, Regeneron Pharmaceuticals, Chugai Pharmaceutical Co Ltd/ Hoffmann-La Roche, Immunovant Inc, Alexion Pharmaceuticals Inc/AstraZeneca, and Janssen, among others.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.